About TYBR Health

TYBR is developing a sprayable hydrogel designed to prevent internal organ scarring after surgical procedures, enhancing the body's natural healing process without synthetic materials. This technology aims to reduce the incidence of function-limiting adhesions, thereby minimizing recovery time and complications for patients.

```xml <problem> Following surgical procedures, internal organ scarring and tissue tethering can impede the body's natural healing process, leading to function-limiting adhesions. These complications can result in extended recovery times, the need for secondary procedures, and reduced patient mobility. </problem> <solution> TYBR Health is developing B3 GEL™, a flowable bio-gel barrier designed to prevent post-surgical tissue tethering and promote optimal healing. This proprietary extracellular matrix (ECM) hydrogel acts as a protective shield for tendons and ligaments during the critical initial healing phase. B3 GEL™ selectively allows essential nutrients and growth factors to reach tissues while blocking excessive scarring. The hydrogel remains in place for the first week post-surgery, protecting tissues through acute inflammation and fibroblast proliferation, and then naturally metabolizes over the following 2-3 weeks, leaving no residual material behind. </solution> <features> - Proprietary extracellular matrix (ECM) hydrogel composition. - Flowable gel for easy application during surgical procedures. - Creates a protective barrier to prevent restrictive scar tissue formation. - Supports optimal tissue healing by allowing essential nutrients and growth factors to reach tissues. - Remains in place for 7 days post-surgery, then metabolizes within 2-3 weeks. - Designed without synthetics to enhance the body’s natural healing capacity. - Suitable for use in hand, wrist, foot, and ankle surgeries. </features> <target_audience> The primary target audience includes surgeons specializing in hand, wrist, foot, and ankle procedures, as well as hospitals and surgical centers focused on improving post-operative outcomes and reducing recovery times. </target_audience> ```

What does TYBR Health do?

When was TYBR Health founded?

TYBR Health was founded in 2020.

Founded

2020

Employees

6 employees

Major Investors

MedTech Innovator

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

TYBR Health

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

tybrhealth.com 1K+

Crunchbase

Founded 2020

Funding

Major Investors

MedTech Innovator

Team (5+)

No team information available.

Company Description

Problem

Following surgical procedures, internal organ scarring and tissue tethering can impede the body's natural healing process, leading to function-limiting adhesions. These complications can result in extended recovery times, the need for secondary procedures, and reduced patient mobility.

Solution

TYBR Health is developing B3 GEL™, a flowable bio-gel barrier designed to prevent post-surgical tissue tethering and promote optimal healing. This proprietary extracellular matrix (ECM) hydrogel acts as a protective shield for tendons and ligaments during the critical initial healing phase. B3 GEL™ selectively allows essential nutrients and growth factors to reach tissues while blocking excessive scarring. The hydrogel remains in place for the first week post-surgery, protecting tissues through acute inflammation and fibroblast proliferation, and then naturally metabolizes over the following 2-3 weeks, leaving no residual material behind.

Features

Proprietary extracellular matrix (ECM) hydrogel composition.

Flowable gel for easy application during surgical procedures.

Creates a protective barrier to prevent restrictive scar tissue formation.

Supports optimal tissue healing by allowing essential nutrients and growth factors to reach tissues.

Remains in place for 7 days post-surgery, then metabolizes within 2-3 weeks.

Designed without synthetics to enhance the body’s natural healing capacity.

Suitable for use in hand, wrist, foot, and ankle surgeries.

Target Audience

The primary target audience includes surgeons specializing in hand, wrist, foot, and ankle procedures, as well as hospitals and surgical centers focused on improving post-operative outcomes and reducing recovery times.